NASDAQ:JAGX Jaguar Health (JAGX) Stock Price, News & Analysis $1.13 +0.01 (+0.89%) (As of 09/11/2024 ET) Add Compare Share Share Today's Range$1.11▼$1.1450-Day Range$1.07▼$4.2752-Week Range$0.95▼$31.74Volume109,404 shsAverage Volume861,839 shsMarket Capitalization$10.44 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Jaguar Health alerts: Email Address Ad Crypto 101 MediaTrader Books $13M Profit on “Nvidia of Crypto”A position trader recently booked an estimated $13.2 million profit on a single crypto currency… This little-known coin, dubbed the "Nvidia of crypto," is fueling the artificial intelligence boom – allowing top companies to train their AI systems without the need for expensive microchips.Click here to review my research and the strategy I've developed for the opportunity to trade this c About Jaguar Health Stock (NASDAQ:JAGX)Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.Read More JAGX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart JAGX Stock News HeadlinesSeptember 4, 2024 | finance.yahoo.comNew Innovators with Jane King Interview with Jaguar Health CEO Lisa Conte Spotlights Company’s Near-Term Commercial & Development MilestonesAugust 27, 2024 | finanznachrichten.deJaguar Health, Inc.: Patent Issued in Jordan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel SyndromeSeptember 11, 2024 | Deal Maker (Ad)Invest before this deal closes on 9/18This company can create aviation fuels from waste, they qualify to help airlines meet net-zero carbon pledges as demand ramps up. The market for this type of fuel is projected to grow 1,500% by 2030. Invest before this investment round closes on 9/18.August 16, 2024 | finance.yahoo.comJaguar Health Second Quarter 2024 Earnings: Misses ExpectationsAugust 15, 2024 | seekingalpha.comJaguar Health, Inc. (JAGX) Q2 2024 Earnings Call TranscriptAugust 15, 2024 | msn.comJaguar Health, Inc. (NASDAQ:JAGX) Q2 2024 Earnings Call TranscriptAugust 14, 2024 | finanznachrichten.deJaguar Health, Inc.: Jaguar Health Reports Second Quarter 2024 Financial ResultsAugust 14, 2024 | msn.comWhy Jaguar Health (JAGX) Stock Is Down 15%September 11, 2024 | Deal Maker (Ad)Invest before this deal closes on 9/18This company can create aviation fuels from waste, they qualify to help airlines meet net-zero carbon pledges as demand ramps up. The market for this type of fuel is projected to grow 1,500% by 2030. Invest before this investment round closes on 9/18.August 12, 2024 | msn.comJaguar Health Q2 2024 Earnings PreviewJuly 23, 2024 | finance.yahoo.comJaguar Health shares slump following Phase III Mytesi failureJuly 23, 2024 | msn.comJaguar Health’s stock slammed after drug that aims to reduce gastro issues in cancer patients fails to meet trial goalsJuly 23, 2024 | nasdaq.comSector Update: Health Care Stocks Advance in Afternoon TradingJuly 23, 2024 | investorplace.comWhy Is Jaguar Health (JAGX) Stock Down 55% Today?July 23, 2024 | investorplace.comWhy Is Jaguar Health (JAGX) Stock Down 55% Today?July 23, 2024 | msn.comCuteness Overload: This Sweet Jaguar Loves Belly RubsJuly 20, 2024 | finance.yahoo.com1JA.F,0P0001DIFR,0 (1JA.F)May 29, 2024 | finanznachrichten.deJaguar Health, Inc.: Jaguar Health Executes Out-License Deal with Joint Venture Magdalena Biosciences for Botanical Drug Candidate for SchizophreniaSee More Headlines Receive JAGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jaguar Health and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/13/2024Today9/11/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:JAGX CUSIPN/A CIK1585608 Webwww.jaguaranimalhealth.com Phone(415) 371-8300FaxN/AEmployees50Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-41,300,000.00 Net Margins-350.18% Pretax Margin-355.51% Return on Equity-412.63% Return on Assets-67.24% Debt Debt-to-Equity Ratio1.32 Current Ratio2.10 Quick Ratio1.60 Sales & Book Value Annual Sales$9.76 million Price / Sales1.05 Cash FlowN/A Price / Cash FlowN/A Book Value$4.02 per share Price / Book0.28Miscellaneous Outstanding Shares9,240,000Free Float4,905,000Market Cap$10.26 million OptionableNo Data Beta0.82 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMs. Lisa A. Conte (Age 65)Founder, CEO, President & Director Comp: $610.66kDr. Pravin R. Chaturvedi Ph.D. (Age 61)Chief Scientific Officer & Chair of Scientific Advisory Board Comp: $517.91kDr. Steven R. King Ph.D. (Age 66)Chief of Sustainable Supply, Ethnobotanical Research & Intellectual Property and Secretary Comp: $406.4kMs. Carol R. Lizak M.B.A. (Age 60)Chief Financial Officer Mr. Peter HodgeSenior Director of Investor Relations, Business Development & Special EventsDr. Karen J. Brunke Ph.D. (Age 71)Executive VP of Corporate & Business Development Mr. Ian H. Wendt M.B.A. (Age 56)Chief Commercial Officer Comp: $441.31kDr. Massimo Radaelli M.B.A. (Age 66)Ph.D., President of Jaguar International Ms. Catherine Miller CollisSenior Vice President of Growth StrategyMore ExecutivesKey CompetitorsCarisma TherapeuticsNASDAQ:CARMKezar Life SciencesNASDAQ:KZRAkari TherapeuticsNASDAQ:AKTXNatural Alternatives InternationalNASDAQ:NAIIZIVO BioscienceNASDAQ:ZIVOView All CompetitorsInstitutional OwnershipPerritt Capital Management IncBought 25,000 shares on 8/8/2024Ownership: 0.510%View All Institutional Transactions JAGX Stock Analysis - Frequently Asked Questions How have JAGX shares performed this year? Jaguar Health's stock was trading at $9.0840 at the beginning of the year. Since then, JAGX stock has decreased by 87.6% and is now trading at $1.13. View the best growth stocks for 2024 here. How were Jaguar Health's earnings last quarter? Jaguar Health, Inc. (NASDAQ:JAGX) posted its quarterly earnings results on Tuesday, August, 13th. The biotechnology company reported ($4.04) earnings per share for the quarter, missing the consensus estimate of ($1.20) by $2.84. The biotechnology company had revenue of $2.72 million for the quarter. Jaguar Health had a negative net margin of 350.18% and a negative trailing twelve-month return on equity of 412.63%. When did Jaguar Health's stock split? Jaguar Health's stock reverse split before market open on Thursday, May 23rd 2024. The 1-60 reverse split was announced on Thursday, May 23rd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. When did Jaguar Health IPO? Jaguar Health (JAGX) raised $22 million in an IPO on Wednesday, May 13th 2015. The company issued 3,200,000 shares at a price of $7.00 per share. Aegis Capital Corp acted as the underwriter for the IPO and CRT Capital and Feltl and Company were co-managers. Who are Jaguar Health's major shareholders? Top institutional investors of Jaguar Health include Perritt Capital Management Inc (0.51%). View institutional ownership trends. How do I buy shares of Jaguar Health? Shares of JAGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Jaguar Health own? Based on aggregate information from My MarketBeat watchlists, some other companies that Jaguar Health investors own include Biocept (BIOC), Sorrento Therapeutics (SRNE), Trevena (TRVN), Vaxart (VXRT), Purple Biotech (KTOV), Onconova Therapeutics (ONTX) and Tonix Pharmaceuticals (TNXP). This page (NASDAQ:JAGX) was last updated on 9/11/2024 by MarketBeat.com Staff From Our PartnersInvest before this deal closes on 9/18This company can create aviation fuels from waste, they qualify to help airlines meet net-zero carbon pledges ...Deal Maker | SponsoredThe #1 Altcoin for September 2024With thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make ...Crypto 101 Media | SponsoredNatural is heading to the NasdaqNatural solutions are already better for the environment. But there’s one company taking it a step further: Th...MedX | SponsoredHow to grow a small trading account into a $100k? Why is Warren Buffett dumping stocks? Billionaires like Warren Buffett, Tim Cook, and Jeff Bezos are offloa...Timothy Sykes | SponsoredWarning For Nvidia HoldersHow The Boeing Disasters Could Hit Nvidia Investors You may have heard about Boeing planes falling apart mi...Stansberry Research | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredRecently listed NASDAQ firm is well positioned for growth with game-changing AI platform for e-commerce.With an innovative AI platform, one tiny but growing NASDAQ firm is ushering in a new e-commerce era and is tr...Smallcaps Daily | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jaguar Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jaguar Health With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
